Lifeboat Foundation

A recent study indicates the prevalence of brain changes from limbic-predominant age-related TDP-43 encephalopathy might be approximately 40% in older adults and as high as 50% in people with Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

PHILADELPHIA — In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The treatment would eradicate their end-stage leukemia, generate headlines across the globe, and usher in a new era of highly personalized medicine. Called Chimeric Antigen Receptor (CAR) T cells, these genetically modified tumor-targeting cells are a living drug made for each patient out of their own cells. Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.

“This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this “living drug” that works effectively against cancer cells,” said first author J. Joseph Melenhorst, PhD, a research professor of Pathology and Laboratory Medicine at Penn. “Witnessing our patients respond well to this innovative cellular therapy makes all of our efforts so worthwhile. being able to give them more time to live and to spend it with loved ones.”

CLL, the first cancer in which CAR T cells were studied and used at Penn, is the most common type of leukemia in adults. While treatment of the disease has improved, it remains incurable with standard approaches. Eventually, patients can become resistant to most therapies, and many still die of their disease.

A network of 1,600 video cameras surveils Marseille residents in the name of public safety, but this type of policing tool is rarely useful in solving crimes. Digital rights activists are fighting back.

For Nano the creep of increased surveillance has personal resonance. She grew up in Albania as it lurched between different political regimes in the 1990s. Her father, a politician, opposed the party that was in power for part of that time. “It was a very difficult period for us, because we were all being watched,” she says. Her family suspected that the authorities had installed bugs in the walls of their home. But even in France, freedoms are fragile. “These past five years France has lived for much of the time in a state of emergency,” she says. “I’ve seen more and more constraints put on our liberty.”

Concerns have been raised throughout the country. But the surveillance rollout has met special resistance in Marseille, France’s second-biggest city. The boisterous, rebellious Mediterranean town sits on some of the fault lines that run through modern France. Known for hip bars, artist studios, and startup hubs, it is also notorious for drugs, poverty, and criminal activity. It has one of the most ethnically diverse populations in Europe but is stranded in Provence-Alpes-Côte d’Azur, a region that leans far right. The city pushes back. Its attitude could be summed up by graffiti you might pass as you drive in on the A7 motorway: “La vie est (re)belle.”

Continue reading “Marseille’s battle against the surveillance state” »

Earlier I posted results. Those posts did not include info here concerning topical E5 human trials to start in a month or so and if the results are good they will start up a U.S. factory. So far, 3 treated rats have a 13% longer lifespan than the max for a lab rat and 3 of them are still alive.

In this video we report on the June 2022 update from Dr. Katcher’s experiment with E5, where he is testing to see how long the rats will stay alive if they are given an E5 injection every 90 days. The experiment appears to be coming to an end with only 3 treated rats still alive. But a new experiment has started as well as a human trial of E5 used topically being planned.

Continue reading “Dr Katcher’s E5 Experiment June 2022 Update | Review” »

Jun Huang from the Pritzker School of Molecular Engineering at the University of Chicago.

Founded in 1,890, the University of Chicago (UChicago, U of C, or Chicago) is a private research university in Chicago, Illinois. Located on a 217-acre campus in Chicago’s Hyde Park neighborhood, near Lake Michigan, the school holds top-ten positions in various national and international rankings. UChicago is also well known for its professional schools: Pritzker School of Medicine, Booth School of Business, Law School, School of Social Service Administration, Harris School of Public Policy Studies, Divinity School and the Graham School of Continuing Liberal and Professional Studies, and Pritzker School of Molecular Engineering.

Irvine, Calif., June 30, 2022 — University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, a common form of hair loss in both women and men.

The study, published online today in Developmental Cell, determined the precise mechanism by which the dermal papilla cells – specialized signal-making fibroblasts at the bottom of each hair follicle – promote new growth. Although it’s well known that dermal papilla cells play a pivotal role in controlling hair growth, the genetic basis of the activating molecules involved has been poorly understood.

“At different times during the hair follicle life cycle, the very same dermal papilla cells can send signals that either keep follicles dormant or trigger new hair growth,” said Maksim Plikus, Ph.D., UCI professor of developmental & cell biology and the study’s corresponding author. “We revealed that the SCUBE3 signaling molecule, which dermal papilla cells produce naturally, is the messenger used to ‘tell’ the neighboring hair stem cells to start dividing, which heralds the onset of new hair growth.”

One of the events hosted by the GRC this year was the conference called ‘Systemic Processes, Omics Approaches, and Biomarkers in Aging.” It was the inaugural Systems Aging Gordon Research Conference. Held in Newry, Maine, this event is not easy to get to. Many of the scientists on the East Coast of the US needed to spend half a day or more just to get there. There is a reason for this. Often, conferences that are organized in large metropolitan areas with easy access do not have the same level of “pressure cooking” and interactive networking just because many senior scientists tend to be distracted and often leave prematurely. But when they are put together in a remote location, it is not easy to leave and they have no choice but to interact with each other, share knowledge, and come up with new ideas and collaborations.

The level and impact of scientific conferences is often evaluated by the number and quality of the sponsors. And the GRC conference on Aging sported a number of high-profile sponsors including GRC itself, Carl Storm International Diversity Fellowship Program, National Institute on Aging, IOMICS Intelligent Analytics, Zymo Research, Kinexum, Insilico Medicine, Illumina, Aging journal, Impetus Grants, Infinita Life Science and VitaDAO.

With Vadim Gladyshev serving as chairman and Steve Horvath as vice-chairman, the conference set the stage for the field, paving the way for the development of interventions to delay and reverse aging. Vadim is a professor of medicine at Harvard Medical School and director of Redox Medicine at Brigham and Women’s Hospital, while Steve is a professor of human genetics and biostatistics at the University of California — Los Angeles, and a senior scientist at Altos Labs. Both are world-renowned researchers, and spoke and led the discussions at the conference.

The first CRISPR gene-editing drug, designed to treat blood disorders, could be on the market by 2023. Here’s what it means for the future of drug development.

The central dogma of molecular biology explains the flow of genetic information, from DNA to RNA, to make a functional product, a protein.

This Video Explains Central Dogma.

Continue reading “Central Dogma” »